×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ZYME – zymeworks inc. (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ZYME
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/12
06:17 am
zyme
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy [Yahoo! Finance]
Low
Report
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy [Yahoo! Finance]
1/12
06:00 am
zyme
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy
Low
Report
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy
1/11
07:40 pm
zyme
Zymeworks Outlines Strategic Priorities and Outlook for 2026 [Yahoo! Finance]
Low
Report
Zymeworks Outlines Strategic Priorities and Outlook for 2026 [Yahoo! Finance]
1/11
06:00 pm
zyme
Zymeworks Outlines Strategic Priorities and Outlook for 2026
Low
Report
Zymeworks Outlines Strategic Priorities and Outlook for 2026
1/6
02:47 pm
zyme
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit [Yahoo! Finance]
Low
Report
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit [Yahoo! Finance]
1/6
01:34 pm
zyme
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit
Low
Report
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit
12/29
07:21 am
zyme
3 Stocks Estimated To Be Priced Below Value In December 2025 [Yahoo! Finance]
Low
Report
3 Stocks Estimated To Be Priced Below Value In December 2025 [Yahoo! Finance]
12/26
07:07 pm
zyme
3 Stocks Estimated To Be Undervalued In December 2025 [Yahoo! Finance]
Low
Report
3 Stocks Estimated To Be Undervalued In December 2025 [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/12
05:00 pm
zyme
Form 144 Zymeworks Inc. Filed by: PATTERSON LEONE D
Neutral
Report
Form 144 Zymeworks Inc. Filed by: PATTERSON LEONE D
1/12
05:00 pm
zyme
Form 144 Zymeworks Inc. Filed by: Galbraith Kenneth
Neutral
Report
Form 144 Zymeworks Inc. Filed by: Galbraith Kenneth
1/12
05:00 pm
zyme
Form 144 Zymeworks Inc. Filed by: Hollywood Mark
Neutral
Report
Form 144 Zymeworks Inc. Filed by: Hollywood Mark
1/12
05:00 pm
zyme
Form 144 Zymeworks Inc. Filed by: Moore Paul Andrew
Neutral
Report
Form 144 Zymeworks Inc. Filed by: Moore Paul Andrew
1/12
05:00 pm
zyme
Form 144 Zymeworks Inc. Filed by: Smith Jeffrey T L
Neutral
Report
Form 144 Zymeworks Inc. Filed by: Smith Jeffrey T L
1/12
04:35 pm
zyme
Form 8-K Zymeworks Inc. For: Jan 06
Neutral
Report
Form 8-K Zymeworks Inc. For: Jan 06
1/7
07:38 pm
zyme
Form 4 Zymeworks Inc. For: Jan 06 Filed by: PATTERSON LEONE D
Medium
Report
Form 4 Zymeworks Inc. For: Jan 06 Filed by: PATTERSON LEONE D
1/5
08:22 pm
zyme
Form 4 Zymeworks Inc. For: Jan 05 Filed by: Smith Jeffrey T L
Medium
Report
Form 4 Zymeworks Inc. For: Jan 05 Filed by: Smith Jeffrey T L
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/16
Form 3 Zymeworks Inc. For: Mar 16 Filed by: 667, L.P.
14.0%
3/23 Form DEF 14A Zymeworks Inc. For: May 07 12.5%
1/28 Form 4 Zymeworks Inc. For: Jan 27 Filed by: Cox Troy 12.5%
3/30 Zymeworks Inc (NYSE: ZYME) was downgraded by analysts at TheStreet from a "c" rating to a "d+" rating. 11.1%
11/22 Zymeworks Highlights Advancing Clinical Collaboration with BeiGene and Updated ZW25 Phase 1 Data in HER2-Expressing Cancers at ESMO Asia Congress 9.7%
6/19 Zymeworks Announces Pricing of $175.0 Million Public Offering 9.6%
1/13 Form 8-K Zymeworks Inc. For: Jan 12 8.8%
2/8 Zymeworks Inc (NYSE: ZYME) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $51.00 price target on the stock. 7.1%
6/20 Form 424B5 Zymeworks Inc. 7.1%
1/21 Form 424B5 Zymeworks Inc. 6.0%
3/23 Form DEF 14A Zymeworks Inc. For: May 07 12.5%
1/28 Form 4 Zymeworks Inc. For: Jan 27 Filed by: Cox Troy 12.5%
3/30 Zymeworks Inc (NYSE: ZYME) was downgraded by analysts at TheStreet from a "c" rating to a "d+" rating. 11.1%
11/22 Zymeworks Highlights Advancing Clinical Collaboration with BeiGene and Updated ZW25 Phase 1 Data in HER2-Expressing Cancers at ESMO Asia Congress 9.7%
6/19 Zymeworks Announces Pricing of $175.0 Million Public Offering 9.6%
1/13 Form 8-K Zymeworks Inc. For: Jan 12 8.8%
2/8 Zymeworks Inc (NYSE: ZYME) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $51.00 price target on the stock. 7.1%
6/20 Form 424B5 Zymeworks Inc. 7.1%
1/21 Form 424B5 Zymeworks Inc. 6.0%
TOP News Decliners
3/16
Zymeworks Appoints Dr. Kelvin Neu to the Board of Directors
-16.2%
3/11 Form 4 Zymeworks Inc. For: Mar 10 Filed by: Tehrani Ali -10.9%
1/23 Zymeworks prices $279M equity offering [Seeking Alpha] -7.7%
2/24 Zymeworks to Present at Raymond James 41st Annual Institutional Investors Conference -7.1%
1/27 Form 424B8 Zymeworks Inc. -7.0%
3/3 Zymeworks Inc (NYSE: ZYME) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -6.7%
6/18 Zymeworks Files Preliminary Prospectus Supplements for Offering of Common Shares and Pre-Funded Warrants -6.7%
11/21 Zymeworks Inc (NYSE: ZYME) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. -5.9%
1/10 Zymeworks Inc (NYSE: ZYME) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $61.00 price target on the stock. -5.9%
5/29 Form SC 13G/A Zymeworks Inc. Filed by: CTI Partners, L.P. -5.2%
3/11 Form 4 Zymeworks Inc. For: Mar 10 Filed by: Tehrani Ali -10.9%
1/23 Zymeworks prices $279M equity offering [Seeking Alpha] -7.7%
2/24 Zymeworks to Present at Raymond James 41st Annual Institutional Investors Conference -7.1%
1/27 Form 424B8 Zymeworks Inc. -7.0%
3/3 Zymeworks Inc (NYSE: ZYME) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -6.7%
6/18 Zymeworks Files Preliminary Prospectus Supplements for Offering of Common Shares and Pre-Funded Warrants -6.7%
11/21 Zymeworks Inc (NYSE: ZYME) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. -5.9%
1/10 Zymeworks Inc (NYSE: ZYME) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $61.00 price target on the stock. -5.9%
5/29 Form SC 13G/A Zymeworks Inc. Filed by: CTI Partners, L.P. -5.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: